Jeevan Scientific Technology Limited has disclosed a significant share transaction by its Executive Director under SEBI takeover regulations. The company filed the mandatory disclosure on March 30, 2026, following an off-market share sale by a key executive.

Share Transaction Details

Executive Director Nageswar Rao Yarlagadda sold 1,00,000 equity shares of the company through an off-market transaction on March 27, 2026. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Changes

The transaction resulted in a significant reduction in Yarlagadda's stake in the company. His shareholding decreased from 1,33,900 shares to 33,900 shares following the sale.

Company Capital Structure

The company's equity share capital structure remained unchanged following the transaction. Jeevan Scientific Technology Limited maintains its total equity share capital at Rs. 19,91,89,650, divided into 1,99,18,965 fully paid-up equity shares of Rs. 10 each.

Regulatory Compliance

The disclosure was filed with BSE Limited, where the company's shares are listed. The Executive Director submitted a formal letter to the exchange along with the prescribed form under Regulation 29(2) of SEBI Takeover Regulations. The seller confirmed that he does not belong to the promoter or promoter group category. The documentation was signed and submitted from Hyderabad on March 30, 2026, ensuring full compliance with regulatory requirements.

Jeevan Scientific Technology Limited has announced the successful completion of the US FDA Remote Regulatory Assessment process and the issuance of the corresponding assessment report. The company informed the BSE through a regulatory filing dated January 22, 2026, marking a significant milestone in its regulatory compliance journey.

FDA Assessment Details

The US FDA conducted a comprehensive Remote Regulatory Assessment and Remote Record Review of the company's clinical pharmacology facility. The assessment covered studies conducted over a specific period and involved detailed scrutiny of the company's operations and compliance standards.

Regulatory Compliance Update

This announcement represents the conclusion of a regulatory process that began earlier in 2025. The company had previously disclosed the commencement of this FDA assessment on November 7, 2025, keeping stakeholders informed throughout the process.

The successful completion of the FDA assessment demonstrates the company's commitment to maintaining international regulatory standards. The Remote Regulatory Assessment Report serves as official documentation of the FDA's review findings regarding the company's clinical pharmacology operations.

Corporate Communication

The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring transparency with investors and regulatory authorities. Managing Director Krishna Kishore Kuchipudi signed the official communication, emphasizing the importance of this regulatory milestone for the organization.

The company's proactive approach to regulatory compliance and transparent communication with exchanges reflects its commitment to maintaining high operational standards in the pharmaceutical sector.